Newsletter

BioMedReports CytRx Announces Publication of Phase 1b/2 Aldoxorubicin; NewLink Genetics Announces Licensing Agreement For De... http://t.co/l9LvyQgryr
15hreplyretweetfavorite
BioMedReports Active Stocks: Advaxis, DexCom, Cytokinetics, Valeant Pharmaceuticals, New Link Genetics: U.S. stocks moved mo... http://t.co/Zhnt4Dj44W
20hreplyretweetfavorite
BioMedReports Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential... http://t.co/p5To7JFYL2
navigation
Benzinga.com supporter Seeking Alpha Certified